{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:22:55Z","timestamp":1790634175692,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T00:00:00Z","timestamp":1527552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s10147-018-1300-9","type":"journal-article","created":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T04:18:34Z","timestamp":1527567514000},"page":"980-988","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Plasma concentrations of dasatinib have a clinical impact on the frequency of dasatinib dose reduction and interruption in chronic myeloid leukemia: an analysis of the DARIA 01 study"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6690-5409","authenticated-orcid":false,"given":"Shuichi","family":"Mizuta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Sawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Tsurumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Miyao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reona","family":"Sakemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Kohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari S.","family":"Oba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiko","family":"Emi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,29]]},"reference":[{"key":"1300_CR1","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","volume":"385","author":"JF Apperley","year":"2015","unstructured":"Apperley JF (2015) Chronic myeloid leukaemia. Lancet 385:1447\u20131459","journal-title":"Lancet"},{"key":"1300_CR2","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/leu.2008.84","volume":"22","author":"A Hochhaus","year":"2008","unstructured":"Hochhaus A, Baccarani M, Deininger M et al (2008) Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 22:1200\u20131206","journal-title":"Leukemia"},{"key":"1300_CR3","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1182\/blood-2012-02-410688","volume":"120","author":"JP Radich","year":"2012","unstructured":"Radich JP, Kopecky KJ, Appelbaum FR et al (2012) A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic phase chronic myeloid leukemia. Blood 120:3898\u20133905","journal-title":"Blood"},{"key":"1300_CR4","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","volume":"119","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Shah NP, Cortes JE et al (2012) Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 119:1123\u20131129","journal-title":"Blood"},{"key":"1300_CR5","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","volume":"123","author":"E Jabbour","year":"2014","unstructured":"Jabbour E, Kantarjian HM, Saglio G et al (2014) Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 123:494\u2013500","journal-title":"Blood"},{"key":"1300_CR6","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM et al (2016) Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol 34:2333\u20132340","journal-title":"J Clin Oncol"},{"key":"1300_CR7","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","volume":"28","author":"D Marin","year":"2010","unstructured":"Marin D, Bazeos A, Mahon FX et al (2010) Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28:2381\u20132388","journal-title":"J Clin Oncol"},{"key":"1300_CR8","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","volume":"111","author":"RA Larson","year":"2008","unstructured":"Larson RA, Druker BJ, Guilhot F et al (2008) Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111:4022\u20134028","journal-title":"Blood"},{"key":"1300_CR9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","volume":"108","author":"T Hughes","year":"2006","unstructured":"Hughes T, Deininger M, Hochhaus A et al (2006) Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108:28\u201337","journal-title":"Blood"},{"key":"1300_CR10","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/j.jchromb.2009.04.028","volume":"877","author":"S Francia De","year":"2009","unstructured":"De Francia S, D\u2019Avolio A, De Martino F et al (2009) New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma. J Chromatogr B Anal Technol Biomed Life Sci 877:1721\u20131726","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"key":"1300_CR11","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3324\/haematol.2012.082511","volume":"99","author":"L Noens","year":"2014","unstructured":"Noens L, Hensen M, Kucmin-Bemelmans I et al (2014) Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges. Haematologica 99:437\u2013447","journal-title":"Haematologica"},{"key":"1300_CR12","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/leu.2016.104","volume":"30","author":"JL Steegmann","year":"2016","unstructured":"Steegmann JL, Baccarani M, Breccia M et al (2016) European Leukemia Net recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukemia. Leukemia 30:1648\u20131671","journal-title":"Leukemia"},{"key":"1300_CR13","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/leu.2010.215","volume":"25","author":"E Jabbour","year":"2011","unstructured":"Jabbour E, Deininger M, Hochhaus A (2011) Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 25:201\u2013210","journal-title":"Leukemia"},{"key":"1300_CR14","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/ajh.23180","volume":"87","author":"EJ Jabbour","year":"2012","unstructured":"Jabbour EJ, Kantarjian H, Eliasson L et al (2012) Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Am J Hematol 87:687\u2013691","journal-title":"Am J Hematol"},{"key":"1300_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/hon.2020","volume":"31","author":"R Latagliata","year":"2013","unstructured":"Latagliata R, Breccia M, Fava C et al (2013) Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukemia. Hematol Oncol 31:103\u2013109","journal-title":"Hematol Oncol"},{"key":"1300_CR16","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.leukres.2014.04.004","volume":"38","author":"AE Eskazan","year":"2014","unstructured":"Eskazan AE, Eyice D, Kurt EA et al (2014) Chronic myeloid leukemia patients who develop grade I\/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion. Leuk Res 38:781\u2013787","journal-title":"Leuk Res"},{"key":"1300_CR17","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1248\/bpb.b15-00103","volume":"38","author":"M Miura","year":"2015","unstructured":"Miura M (2015) Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia. Biol Pharm Bull 38:645\u2013654","journal-title":"Biol Pharm Bull"},{"key":"1300_CR18","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s40262-014-0137-2","volume":"53","author":"H Yu","year":"2014","unstructured":"Yu H, Steeghs N, Nijenhuis CM et al (2014) Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets. Clin Pharmacokinet 53:305\u2013325","journal-title":"Clin Pharmacokinet"},{"key":"1300_CR19","first-page":"85","volume":"5","author":"X Wang","year":"2013","unstructured":"Wang X, Roy A, Hochhaus A et al (2013) Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure\u2013response analysis of a Phase III study. Clin Pharmacol 5:85\u201397","journal-title":"Clin Pharmacol"},{"key":"1300_CR20","unstructured":"Rousselot P, Mollica L, Guerci-Bresler A et al (2014) Dasatinib daily dose optimization based on residual drug levels resulted in reduced risk of pleural effusions and high molecular response rates: final results of the randomized OPTIM dasatinib Trial. Abstract ABSSUB-5297, Congress of the European Hematology Association (EHA)"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-018-1300-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-018-1300-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-018-1300-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T20:47:51Z","timestamp":1559076471000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-018-1300-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,29]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["1300"],"URL":"https:\/\/doi.org\/10.1007\/s10147-018-1300-9","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,29]]},"assertion":[{"value":"16 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Masashi Sawa received honoraria from Bristol-Myers Squibb. Hiroshi Kojima received honoraria from Celgene. Satoshi Morita received honoraria from Bristol-Myers Squibb. Junichi Sakamoto received honoraria from Tsumura and Chugai Pharmaceutical, and has received consultancy fees from Takeda. Nobuhiko Emi received honoraria from Kyowa Hakko Kirin and Chugai Pharmaceutical. All other authors report no conflicts of interest relevant to this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The present study was approved by the Institutional Review Board of the Fujita Health University School of Medicine and conformed to the provisions of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. All patients provided written, informed consent before participating in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}